The Arora Report

March 3, 2021

BIOLOGICAL TESTING PRODUCTS COMPANY LMNX BECOMES A BUYOUT TARGET

Luminex Corporation (LMNX) has become a buyout target. There is an 80% probability of a deal ultimately happening. LMNX is trading at $32.09 as of this writing. The most likely acceptable bid is in the zone of $38 to $42. If a bidding war erupts, the stock can go higher.

In the world of investing there no free lunch. The issue here is that the stock can easily trade in the range of $21 to $34 in the interim. A good way to handle this situation is to scale in with small tranches such as 5%. The maximum recommended quantity is 50% of full core position size. … Please click here or the title below to read more.

March 3, 2021

MORE GAINS AHEAD – 63% GAIN ON THIS SUPPLIER OF A KEY COMPONENT FOR VACCINE

Maravai LifeSciences (MRVI) is long from $25.84. MRVI is trading at $42.25 as of this writing. This represents a gain of 63% in a short time.

MRVI reported earnings significantly better than the consensus.

We have previously written that the target zone was likely to be raised.

MRVI supplies a key component of the coronavirus vaccine produced by Pfizer (PFE) and BioNTech (BNTX). The vaccine should provide a sharp increase in revenue. The company also has a diversified product portfolio.